BioSpace News Archive

Locus Biosciences announced that it has signed a contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator to fund up to $12.5 million of a $14.8 million program for development of LBP-KP01, a CRISPR Cas3-enhanced bacteriophage product targeting the bacterial pathogen Klebsiella pneumoniae.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber,

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company’s pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference, to be held virtually Nov. 11-13, 2020.

Study recently published by Penn team in Cell Reports provides evidence that NLY01 has the potential for clinical use in the treatment of glaucoma and potentially other retinal diseases

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). FT-4202 was previously

Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek will participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference, Monday, November 16, 2020 at 10:40 a.m. ET. The conference will be held in a virtual meeting format, and one-on-one meetings will be held before and immediately following the fireside chat. A live audio webcast will be

Late Breaker to be Presented by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital A Total of Three Abstracts Highlighting AU-011 Selected for Presentation

Third Quarter 2020 GAAP Revenue of $143 million Third Quarter 2020 GAAP Net Income of $8 million Third Quarter 2020 GAAP Diluted Earnings Per Share of $0.23 Third Quarter 2020 Adjusted Earnings Per Share of $0.42 Third Quarter 2020 Adjusted EBITDA of $30 million

First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that Chris Martin, Chief Executive Officer, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on Novem